secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0000950170-22-009706
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022
--------------------------------------------------------------------------------

- Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.
- R&D expenses $8.3M (up from $4.2M) and G&A $4.5M (up from $1.7M), driven by manufacturing and public company costs.
- Plan to initiate pivotal trial for AU-011 in choroidal melanoma in 2H 2022; European Commission granted Orphan Drug Designation for uveal melanoma.
- IND submission for choroidal metastases and Phase 1 trial in NMIBC expected in 2H 2022, with initial data in 2023.
- Preclinical data at ASCO and AACR show AU-011's broad tumor targeting and combination potential with checkpoint inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/0000950170-22-009706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/aura-20220512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer